U.S. stock night market volatility: FDA restarts review + rating upgrade, Capricor surges 58%Price Alert·1 day ago, 08:46 PMCAPR-4.97%
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk ReductionPR Newswire·Jul 14 at 03:30 AMBIOA+0.58%6882220.00%
